MDXHMDxHealth SAvs its industry peers
A metric-by-metric comparison of MDxHealth SA against SIC 8071 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDXH본 종목 | $34M#1 | — | — | 0.3x#1 | 19.8%#4 | 12.0%#3 | -13.4%#4 | — | — | — | -81.7%#3 | — |
| ADVB | $11M#2 | 1.1x#1 | 1.2x#5 | — | — | -17.1%#6 | — | -35.4%#4 | — | — | -20.8%#1 | — |
| AMS | $10M#3 | — | 0.4x#2 | 0.3x#2 | -0.9%#6 | -171.0%#8 | -12.8%#3 | -6.7%#2 | -21.2%#2 | 4#1 | — | — |
| ACON | $7M#4 | — | 0.4x#3 | 96.5x#5 | 65.6%#2 | -3.4%#4 | -9312.5%#6 | -42.5%#6 | — | — | — | — |
| BGLC | $5M#5 | — | 0.6x#4 | 0.6x#3 | -21.9%#7 | -86.7%#7 | -39.9%#5 | -38.4%#5 | — | — | -67.1%#2 | — |
| ACONW | $73789#6 | — | 0.0x#1 | 1.0x#4 | 65.6%#2 | -3.4%#4 | -9312.5%#6 | -42.5%#6 | — | — | — | — |
| BNR | — | — | — | — | 9.2%#5 | 83.3%#2 | -10.2%#2 | -10.3%#3 | — | — | — | — |
| CFOR | — | — | — | — | 481.2%#1 | 97.0%#1 | 79.6%#1 | 31.8%#1 | 26.3%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 8071). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice